Biological drugs are complex molecules made in living cells, and they have changed medicine in the past two decades, offering rich choices for companies making almost identical copies as patents expire.
Last year, insiders said that Pfizer considered whether to sell, spin off or keep its Consumer Healthcare Business. Now, those same insiders say Johnson & Johnson has decided it’s no longer interested.
Sick and tired of dealing with generic drug shortages and unpredictable price increases, five large U.S. health systems are taking an unusual step: they’re forming their own nonprofit generic drugmaker.
The good thing about J.P. Morgan Week is that it draws innovative people who want to invest. The question is, should healthcare capital be focused on solving big problems and getting rewarded for them, or just focused on the status quo?
Researchers have developed a new way to attack cancer: using a non-toxic dose of sodium formate—found in nettles and ants—to trigger an organic-osmium compound.
In a new study, melanoma patients who received immunotherapy while taking a specific type of beta blocker lived longer than patients who received immunotherapy alone, researchers report.
It has been widely reported that bacteria will evolve to render antibiotics mostly ineffective by mid-century—and current strategies to make up for the projected shortfalls haven’t worked.
Johnson & Johnson decided to kick start the new year by striking 15 new collaborations to drive the development of novel solutions to impact healthcare.
Alnylam Pharmaceuticals have announced a strategic restructuring of their RNAi therapeutics alliance with French pharmaceuticals company, Sanofi.
With drug development and other treatments, outcomes for the vast majority of diseases have improved over the past few decades, while life expectancy for sickle cell patients has declined.
A drug developed for type 2 diabetes has “significantly reversed memory loss” in mice with Alzheimer’s disease, and researchers now want to test it on humans.